BALANCE SHEET COMPONENTS

The following table provides the Company's unbilled receivables and deferred revenues from contracts with customers:



(In millions)	June 29, 2018			September 29, 2017
Unbilled receivables - current	$	343.0		$	259.1
Unbilled receivables - long-term ⁽¹⁾	27.4			10.9
Deferred revenues - current	(790.2		)	(755.4		)
Deferred revenues - long-term ⁽²⁾	(9.6		)	(7.2		)
Total net unbilled receivables (deferred revenues)	$	(429.4	)	$	(492.6	)


⁽¹⁾	Included in other assets on the Company's Condensed Consolidated Balance Sheets.


⁽²⁾	Included in other long-term liabilities on the Company's Condensed Consolidated Balance Sheets.

During the nine months ended June 29, 2018, unbilled receivables net of deferred revenues increased by $63.2 million primarily due to the contractual timing of billings occurring after the revenues were recognized, as well as the timing of milestone payments.

During the three and nine months ended June 29, 2018, the Company recognized revenues of $214.3 million and $519.5 million, respectively, which was included in the deferred revenues balance at September 29, 2017. During the three and nine months ended June 30, 2017, the Company recognized revenues of $109.0 million and $455.0 million, respectively, which was included in the deferred revenues balance at September 30, 2016.

The Company did not have any impairment losses on its unbilled receivables during the nine months ended June 29, 2018. The Company recognized an impairment loss of $17.2 million from long-term unbilled receivables during the nine months ended June 30, 2017. See Note 16, "VPT Loans and Investment" for further information.

The following table summarizes the Company's inventories:



(In millions)	June 29, 2018		September 29, 2017
Raw materials and parts	$	334.4	$	296.5
Work-in-process	54.2		47.7
Finished goods	80.6		73.5
Total inventories	$	469.2	$	417.7

The following tables summarize the Company's cash equivalents and available-for-sale securities:



	June 29, 2018
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash equivalents:
Money market funds	$	155.8	$	—	$	—	$	155.8
Total cash equivalents	$	155.8	$	—	$	—	$	155.8

Available-for-sale securities:
APTC securities ⁽¹⁾	$	6.3	$	—	$	—	$	6.3
GPTC securities ⁽²⁾	4.6		—		—		4.6
Total available-for-sale securities	$	10.9	$	—	$	—	$	10.9



	September 29, 2017
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale securities:
Original CPTC loans ⁽²⁾	$	47.4	$	—	$	—	$	47.4
DRTC securities⁽²⁾	8.3		—		—		8.3
GPTC securities ⁽²⁾	4.4		—		—		4.4
Total available-for-sale securities	$	60.1	$	—	$	—	$	60.1


⁽¹⁾	Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets because the Company has the ability and intent to sell this security in the next twelve months.


⁽²⁾	Included in other assets on the Company's Condensed Consolidated Balance Sheets because the maturity dates are greater than one year and the Company does not have the intent and ability to collect or sell all or a portion of its loans or securities in the next twelve months.

See Note 5, "Fair Value" and Note 16, "VPT Loans and Investment" for more information on the Original California Proton Treatment Center, LLC (“Original CPTC”) Loans, Alabama Proton Therapy Center (“APTC”), Delray Radiation Therapy Center (“DRTC”), and Georgia Proton Treatment Center ("GPTC") Securities.

The following table summarizes the Company's other long-term liabilities:



(In millions)	June 29, 2018		September 29, 2017
Long-term income taxes payable	$	201.1	$	48.6
Deferred income taxes	28.1		17.1
Other	62.0		61.7
Total other long-term liabilities	$	291.2	$	127.4